Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
2012; Springer Science+Business Media; Volume: 30; Issue: 6 Linguagem: Inglês
10.1007/s10637-011-9772-8
ISSN1573-0646
AutoresChristophe Massard, Ramón Salazar, Jean‐Pierre Armand, Margarita Majem, Éric Deutsch, Montse García, Ana Oaknin, Eva M. Fernández‐García, A. Soto, Jean‐Charles Soria,
Tópico(s)Cancer Genomics and Diagnostics
Referência(s)